Drug intelligence / Profile preview

Pelprazole

Development stage: Unknown
Lead developer: Jay Ell Healthcare
Modality: Small Molecules
Administration: Oral

Overview

Pelprazole is an oral, gastro-resistant formulation of pantoprazole, a small molecule proton pump inhibitor (PPI). Developed and marketed by Jay Ell Healthcare, it is used to treat acid-related disorders such as gastroesophageal reflux disease (GERD), heartburn, and hyperacidity. The drug works by irreversibly inhibiting the gastric H+/K+ ATPase enzyme (the proton pump) in the parietal cells of the stomach, thereby reducing gastric acid secretion. It is typically administered as a 40mg enteric-coated tablet to ensure the active ingredient bypasses the acidic environment of the stomach and is released in the intestines for absorption.

Brand names: Pelprazole

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on Pelprazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pelprazole.

Explore the full profile